Notable Friday Option Activity: U, OKTA, HROW

Okta (OKTA) options saw 13,284 contracts traded today (≈1.3 million underlying shares), equal to roughly 52.9% of OKTA's one‑month ADTV of 2.5M shares; the most active contract was the $91 put expiring Jan 16, 2026 with 1,939 contracts (~193,900 shares). Harrow Inc (HROW) recorded 3,058 option contracts (~305,800 underlying shares), about 52.6% of its one‑month ADTV of 581,730 shares, led by the $55 call expiring Feb 20, 2026 with 1,106 contracts (~110,600 shares). The concentration of volume in specific strikes and expirations suggests elevated speculative positioning that could affect near‑term liquidity and intraday price moves in the underlying equities.

Analysis

Market structure: Very large single-day option flow (OKTA ~13,284 contracts ≈1.3M shares = 52.9% of ADV; HROW ~3,058 contracts ≈305.8k shares = 52.6% of ADV) concentrates risk at single strikes ($91 put Jan 16, 2026 for OKTA; $55 call Feb 20, 2026 for HROW). Immediate beneficiaries are directional options buyers and liquidity providers; short-term holders of the underlying face elevated gamma-driven moves as market makers delta-hedge. Cross-asset: expect equity volatility to rise for both names, modest idiosyncratic spill to sector peers; macro (bonds/FX/commodities) impact is negligible absent a larger tech selloff.

Risk assessment: Tail risks include an Okta breach or customer contract loss that could realize the heavy put positioning (high-impact, low-probability) and regulatory or clinical/approval setbacks for HROW analogues. Time horizons: days — price pinning and gamma; weeks–months — IV reprice and earnings/announcements; quarters — fundamentals reassert. Hidden dependencies: flows may be institutional hedges, single-block trades, or dispersion trades — not pure directional bets; sizable IV compression if market makers net-sell options could punish buyers.

Trade implications: For OKTA, prefer defined-risk bearish exposure via Jan 16, 2026 91/71 put spread (buy) sized 1–2% portfolio, target 30–50% realized P&L or roll/close 60 days before expiry; avoid naked short puts. For HROW, take a bullish Feb 20, 2026 55/65 call vertical (buy) size 1–2%, trim at 40% gain or if IV falls >30%. Pair trade: long HROW call spread / short (or hedge) OKTA put spread to exploit relative skew; consider adding only while flow persists (next 5 trading days).

Contrarian angles: Consensus may treat OKTA flow as pure bearish conviction but could be portfolio insurance — downside is likely overstated absent a catalyst; large single-strike flow historically creates short-term exaggerated moves then mean reversion. If IV spikes >40% and no news, selling premium (calendar or vertical spreads) can be profitable; unintended consequence: crowded put-buying can create transient liquidity squeezes on rebounds, so manage gamma risk tightly.

Key Decisions for Investors

• Initiate a defined-risk bearish position in OKTA: buy Jan 16, 2026 91/71 put spread (2:1 width) sized to 1% of portfolio notional; target 30–50% profit, stop-loss at 2× premium paid or if implied vol falls >30%.
• Establish a bullish position in HROW: buy Feb 20, 2026 55/65 call spread representing ~1% portfolio; scale in over next 5 trading days while open interest builds, trim at 40% gain or if IV compresses >25%.
• Construct a relative-value pair: long HROW Feb20 55/65 call spread and long-protection via short-dated OKTA Jan16 91/86 put spread (smaller notional) to exploit skew differences; net exposure max 2% portfolio and rebalance weekly.
• If IV for either name spikes >40% without fundamental news, sell premium via 3–6 month iron condors/verticals sized conservatively (max 0.5% portfolio per trade) and close if position reaches 30% of max profit or 60 days to expiry.